X4 Pharmaceuticals Files Definitive Proxy Statement
Ticker: XFOR · Form: DEF 14A · Filed: Mar 24, 2025 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | DEF 14A |
| Filed Date | Mar 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, shareholder-meeting
TL;DR
X4 Pharma's proxy statement is in, shareholders get to vote soon.
AI Summary
X4 Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on March 24, 2025, for its annual meeting. The company, formerly known as Arsanis, Inc., is based in Boston, MA, and operates in the biological products sector. The filing details information related to the solicitation of proxies for the meeting.
Why It Matters
This filing provides shareholders with essential information to vote on company matters at the upcoming annual meeting, impacting corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new financial risks.
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- Arsanis, Inc. (company) — Former Company Name
- 20250324 (date) — Filing Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing them with information to make informed voting decisions.
When was this DEF 14A filed by X4 Pharmaceuticals, Inc.?
X4 Pharmaceuticals, Inc. filed this DEF 14A on March 24, 2025.
What was X4 Pharmaceuticals, Inc. formerly known as?
X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc.
Where is X4 Pharmaceuticals, Inc. located?
X4 Pharmaceuticals, Inc. is located at 61 North Beacon Street, 4th Floor, Boston, MA 02134.
What is the Standard Industrial Classification (SIC) code for X4 Pharmaceuticals, Inc.?
The SIC code for X4 Pharmaceuticals, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 24, 2025 regarding X4 Pharmaceuticals, Inc (XFOR).